Lilly sues six companies over retatrutide knockoff sales
The suits target sellers marketing copies of Lilly's investigational triple agonist, which is not approved by the FDA.
DO
By Daniel Okafor · Regulatory Correspondent
Aug 12 03:00 ETSource: Fierce Pharma
The wire
- 01Eli Lilly has filed court actions against six companies it accuses of selling knockoff versions of retatrutide, its investigational GIP/GLP-1/glucagon triple agonist.
- 02Retatrutide has no FDA approval, so any product sold under that name sits outside the regulated supply chain that pharmacists and telehealth prescribers rely on.
- 03Outcomes of the litigation, and whether more sellers are named, remain to be seen; details beyond the filings themselves are limited.
From the source
Read at fiercepharma.comLilly takes 6 companies to court for selling retatrutide knockoffs